Gastrinomas: Medical or Surgical Treatment

Jeffrey A Norton; Deshka S Foster; Tetsuhide Ito; Robert T Jensen

doi:10.1016/j.ecl.2018.04.009

Gastrinomas: Medical or Surgical Treatment

Endocrinol Metab Clin North Am. 2018 Sep;47(3):577-601. doi: 10.1016/j.ecl.2018.04.009.

Authors

Jeffrey A Norton¹, Deshka S Foster¹, Tetsuhide Ito², Robert T Jensen³

Affiliations

¹ Department of Surgery, Stanford University School of Medicine, 291 campus Drive, Stanford, CA 94305-5101, USA.
² Neuroendocrine Tumor Centra, Fukuoka Sanno Hospital, International University of Health and Welfare, 3-6-45 Momochihama, Sawara-Ku, Fukuoka 814-0001, Japan.
³ Digestive Diseases Branch, NIDDK, National Institutes of Health, Building 10, Room 9C-103, Bethesda, MD 20892-1804, USA. Electronic address: robertj@bdg10.niddk.nih.gov.

Abstract

This article reviews the role of surgical and medical management in patients with Zollinger-Ellison syndrome (ZES) due to a gastrin-secreting neuroendocrine tumor (gastrinoma). It concentrates on the status at present but also briefly reviews the changes over time in treatment approaches. Generally, surgical and medical therapy are complementary today; however, in some cases, such as patients with ZES and multiple endocrine neoplasia type 1, the treatment approach remains controversial.

Keywords: Acid secretion; Gastrinoma; Multiple endocrine neoplasia type 1; Neuroendocrine tumor; Proton pump inhibitors; Zollinger-Ellison syndrome.

Published by Elsevier Inc.

Publication types

Review

MeSH terms

Gastrinoma / drug therapy*
Gastrinoma / surgery*
Humans
Multiple Endocrine Neoplasia Type 1 / drug therapy
Multiple Endocrine Neoplasia Type 1 / surgery
Neuroendocrine Tumors / drug therapy*
Neuroendocrine Tumors / surgery*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / surgery*
Zollinger-Ellison Syndrome / drug therapy*
Zollinger-Ellison Syndrome / surgery*

Abstract

Publication types

MeSH terms

Grants and funding